Andrew Knudten
Chief Tech/Sci/R&D Officer bei Cirius Therapeutics, Inc.
Profil
Herr Andrew Knudten ist Chief Operating Officer bei Jaguar Gene Therapy LLC und Chief Technical Officer bei Cirius Therapeutics, Inc. Herr Knudten war zuvor als Chief Technical Officer & SVP-Technical Operations bei AveXis, Inc., als Vice President-Operations & Plant Manager bei Hospira, Inc., als Global Head-Contract Manufacturing bei Novartis AG, als Vice President-Manufacturing bei CoDa Therapeutics, Inc. und als Operations Director bei Amgen, Inc. tätig. Er erhielt seinen Bachelor-Abschluss von der Concordia University, einen Master-Abschluss von der University of Nebraska und einen MBA von der UCLA Anderson School of Management.
Aktive Positionen von Andrew Knudten
Unternehmen | Position | Beginn |
---|---|---|
Cirius Therapeutics, Inc.
Cirius Therapeutics, Inc. BiotechnologyHealth Technology Cirius Therapeutics, Inc. operates as a biotechnology company. It offers metabolic treatment for nonalcoholic steatohepatitis. The company was founded by Jerry R. Colca and Brian Finck and was founded in March 2017, and is headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | 03.06.2019 |
Jaguar Gene Therapy LLC
Jaguar Gene Therapy LLC Medical/Nursing ServicesHealth Services Jaguar Gene Therapy LLC is a company that aims to accelerate breakthroughs in gene therapy for patients suffering from severe genetic diseases. The company is based in Lake Forest, IL. The company's unrelenting commitment is to advocate boldly and care fiercely for patients and families. The company works together to confront the challenges of treating complex diseases and are advancing their initial pipeline that targets diseases with significant unmet need in sizeable patient populations. Joseph Nolan has been the CEO of the company since 2020. | Chief Operating Officer | 01.02.2020 |
Ehemalige bekannte Positionen von Andrew Knudten
Unternehmen | Position | Ende |
---|---|---|
HOSPIRA, INC. | Corporate Officer/Principal | 01.09.2015 |
NOVARTIS AG | Corporate Officer/Principal | 01.03.2012 |
OcuNexus Therapeutics, Inc.
OcuNexus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology OcuNexus Therapeutics, Inc. develops and commercializes therapeutic products for wound care and tissue repair. The firm offers Nexagon, an oligonucleotide that downregulates the gap junction in tissue repair. Its Nexagon also reduces lesion spread, swelling, inflammation, scarring, and time to wound closure in various tissue types, including the eye, skin, spinal cord, nerve, and brain. The company was founded in 2005 by David Lawrence Becker, Colin C. Green and Bradford J. Duft and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01.02.2009 |
AMGEN INC. | Chief Operating Officer | 01.01.2007 |
AVEXIS INC | Chief Tech/Sci/R&D Officer | - |
Ausbildung von Andrew Knudten
University of Nebraska | Graduate Degree |
Concordia University | Undergraduate Degree |
UCLA Anderson School of Management | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
AMGEN INC. | Health Technology |
NOVARTIS AG | Health Technology |
Private Unternehmen | 5 |
---|---|
Hospira, Inc.
Hospira, Inc. Pharmaceuticals: MajorHealth Technology Hospira, Inc. provides injectable drugs and infusion technologies. It offers drugs, IV sets and clinical integration, infusion pumps, clinical software and implementation services. The company was founded on September 16, 2003 and is headquartered in Lake Forest, IL. | Health Technology |
OcuNexus Therapeutics, Inc.
OcuNexus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology OcuNexus Therapeutics, Inc. develops and commercializes therapeutic products for wound care and tissue repair. The firm offers Nexagon, an oligonucleotide that downregulates the gap junction in tissue repair. Its Nexagon also reduces lesion spread, swelling, inflammation, scarring, and time to wound closure in various tissue types, including the eye, skin, spinal cord, nerve, and brain. The company was founded in 2005 by David Lawrence Becker, Colin C. Green and Bradford J. Duft and is headquartered in San Diego, CA. | Health Technology |
Novartis Gene Therapies, Inc.
Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
Cirius Therapeutics, Inc.
Cirius Therapeutics, Inc. BiotechnologyHealth Technology Cirius Therapeutics, Inc. operates as a biotechnology company. It offers metabolic treatment for nonalcoholic steatohepatitis. The company was founded by Jerry R. Colca and Brian Finck and was founded in March 2017, and is headquartered in San Diego, CA. | Health Technology |
Jaguar Gene Therapy LLC
Jaguar Gene Therapy LLC Medical/Nursing ServicesHealth Services Jaguar Gene Therapy LLC is a company that aims to accelerate breakthroughs in gene therapy for patients suffering from severe genetic diseases. The company is based in Lake Forest, IL. The company's unrelenting commitment is to advocate boldly and care fiercely for patients and families. The company works together to confront the challenges of treating complex diseases and are advancing their initial pipeline that targets diseases with significant unmet need in sizeable patient populations. Joseph Nolan has been the CEO of the company since 2020. | Health Services |